Massachusetts District Court Rules for Amgen in Bone Biology Patent Dispute
What would you like to do next?
Choose your path based on your current needs:
📋 Case Summary
| Case Name | OssiFi-Mab, LLC v. Amgen, Inc. |
| Case Number | 1:23-cv-10861 (D. Mass.) |
| Court | District of Massachusetts, Chief Judge Denise J. Casper |
| Duration | Apr 2023 – Feb 2026 2 years 10 months |
| Outcome | Defendant Win – Amgen |
| Patents at Issue | |
| Accused Products | Amgen’s Evenity® (romosozumab) – sclerostin-targeting monoclonal antibody |
Case Overview
The Parties
⚖️ Plaintiff
Patent holding entity asserting intellectual property in the bone biology space. As a non-practicing entity (NPE), its business model centers on licensing and litigation.
🛡️ Defendant
Global biopharmaceutical leader headquartered in Thousand Oaks, California. Amgen’s bone biology portfolio includes Evenity® (romosozumab), a sclerostin-targeting monoclonal antibody.
The Patents at Issue
OssiFi-Mab asserted four U.S. patents covering methods of altering bone growth through administration of SOST or WISE antagonists and agonists:
- • US11807681B2 — Methods of altering bone growth via SOST or WISE antagonists/agonists
- • US11608373B2 — Methods of altering bone growth via SOST or WISE antagonists/agonists
- • US8178099B2 — Methods of altering bone growth via SOST or WISE antagonists/agonists
- • US8877196B2 — Methods of altering bone growth via SOST or WISE antagonists/agonists
Developing a biologics therapeutic?
Check if your therapeutic might infringe these or related patents.
Litigation Timeline & Procedural History
OssiFi-Mab filed suit on April 21, 2023, choosing the District of Massachusetts — a jurisdiction with an experienced patent docket and Chief Judge Denise J. Casper, a seasoned federal jurist known for active case management.
The case ran for 1,043 days (approximately 34 months) before closing, a duration consistent with complex first-instance patent litigation involving multiple patents and sophisticated scientific subject matter. This timeline typically encompasses early motion practice, claim construction, discovery, and dispositive motion briefing.
The case was resolved at the district court (first instance) level, with the final judgment entered February 27, 2026, pursuant to a Memorandum and Order issued three days earlier on February 24, 2026 (D. 303). The court-decided — rather than jury-decided — outcome suggests resolution via summary judgment or bench ruling on dispositive legal issues rather than a full trial on the merits.
The Verdict & Legal Analysis
Outcome
Chief Judge Denise J. Casper entered judgment for defendant Amgen, Inc. The court’s Memorandum and Order (D. 303, February 24, 2026) preceded the formal judgment by three days, indicating a fully reasoned written decision rather than a procedural dismissal.
Verdict Cause Analysis
The case was litigated as a direct infringement action across four patents in the SOST/WISE antagonist space. While the specific legal basis of the court’s ruling (e.g., non-infringement, invalidity, or both) is drawn from the Memorandum and Order at D. 303 — a document that would detail claim construction rulings and infringement findings — the structure of the litigation is instructive.
In biologics method-of-treatment patent cases involving NPE plaintiffs and large pharma defendants, outcomes favorable to defendants commonly turn on one of three grounds: **Claim Construction**, **Invalidity** (particularly where foundational science predates patent priority dates), or **Non-Infringement on the Merits**.
Legal Significance
This case sits at the intersection of **foundational biologics patents** and **method-of-treatment claim scope** — an area of persistent litigation complexity. The Amgen victory reinforces a pattern where well-resourced pharma defendants successfully defend against NPE assertions in method-of-treatment biologics cases, particularly when multi-firm defense teams mount coordinated validity and non-infringement challenges.
Drafting biologics method claims?
Learn from this case. Use AI to draft stronger claims that can withstand litigation.
Power Your Patent Strategy with PatSnap Eureka IP
From novelty searches to patent drafting, PatSnap Eureka’s AI-powered tools help you navigate the patent landscape with confidence.
⚠️ Freedom to Operate (FTO) Analysis
This case highlights critical IP risks in biologics development. Choose your next step:
📋 Understand This Case’s Impact
Learn about specific risks and implications from this litigation related to biologics.
- View all 4 patents and family members in this technology space
- See which companies are active in sclerostin inhibition
- Understand biologics claim construction patterns
🔍 Check My Product’s Risk
Run a comprehensive FTO analysis for your own biologic or therapeutic.
- Input your product description or biological target
- AI identifies potentially blocking patents
- Get actionable risk assessment report
High Risk Area
SOST/sclerostin pathway targeting biologics
4 Asserted Patents
In bone biology method space
Strategy for IP Management
Proactive FTO essential for biologics
✅ Key Takeaways
For Patent Attorneys
Court-decided judgment for Amgen suggests resolution on legal rather than factual grounds — claim construction and validity likely pivotal.
Search related biologics case law →Multi-firm defense coordination is a replicable strategy for high-value pharma patent defense.
Explore defense strategies →NPE assertions on foundational biologics method patents face substantial validity exposure given dense prior art.
Analyze biologics prior art →Four-patent assertion strategies require proportionate resource allocation from plaintiffs.
Evaluate litigation costs →For R&D Teams
Conduct updated FTO analysis for any therapeutic programs targeting the SOST/sclerostin pathway.
Start FTO analysis for my biologic →Continuation patent families (like those asserted here) require ongoing prosecution monitoring.
Track patent family status →Ready to Strengthen Your Patent Strategy?
Join thousands of IP professionals using PatSnap Eureka to conduct prior art searches, draft patents, and analyze competitive landscapes.